Recently Viewed

  • Home
  • Stories
  • News Announcement
  • Concord Biotech: Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Mycophenolate Mofetil For Oral Suspension USP 200 Mg/Ml
News Announcement

Concord Biotech: Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Mycophenolate Mofetil For Oral Suspension USP 200 Mg/Ml

02-Jun-2026 Follow Value Research Online on Google download pdfDownload PDF Concord Biotech

We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP 200 mg/mL.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.